Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
Status:
Completed
Trial end date:
2015-03-25
Target enrollment:
Participant gender:
Summary
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days
treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The
standard regimen is twice daily for three days with a delay of at least eight hours between
the first and second doses. A single of primaquine will be given to all patients on the first
day of treatment for gametocytocidal activity. The initial treatment will be given under
supervision, all other subsequent doses will be given to the patient to the taken at home.
Patients will be followed up for nine visits over forty two days.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oxford
Treatments:
Artemether Artemether-lumefantrine combination Artemether, Lumefantrine Drug Combination Artemisinins Lumefantrine